These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 11259165)

  • 1. Phosphorylation-dependent conformation and proteolytic stability of c-Myb.
    Bies J; Feiková S; Markus J; Wolff L
    Blood Cells Mol Dis; 2001; 27(2):422-8. PubMed ID: 11259165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases.
    Bies J; Feiková S; Bottaro DP; Wolff L
    Oncogene; 2000 Jun; 19(24):2846-54. PubMed ID: 10851088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive ubiquitination and degradation of c-myb by the 26S proteasome during proliferation and differentiation of myeloid cells.
    Feiková S; Wolff L; Bies J
    Neoplasma; 2000; 47(4):212-8. PubMed ID: 11043824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38MAPK delta controls c-Myb degradation in response to stress.
    Pani E; Ferrari S
    Blood Cells Mol Dis; 2008; 40(3):388-94. PubMed ID: 18006338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway.
    Bies J; Wolff L
    Oncogene; 1997 Jan; 14(2):203-12. PubMed ID: 9010222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional SUMO-interacting motif in the transactivation domain of c-Myb regulates its myeloid transforming ability.
    Saether T; Pattabiraman DR; Alm-Kristiansen AH; Vogt-Kielland LT; Gonda TJ; Gabrielsen OS
    Oncogene; 2011 Jan; 30(2):212-22. PubMed ID: 20802522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR structure of the hRap1 Myb motif reveals a canonical three-helix bundle lacking the positive surface charge typical of Myb DNA-binding domains.
    Hanaoka S; Nagadoi A; Yoshimura S; Aimoto S; Li B; de Lange T; Nishimura Y
    J Mol Biol; 2001 Sep; 312(1):167-75. PubMed ID: 11545594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIPK1 interacts with c-Myb and modulates its activity through phosphorylation.
    Matre V; Nordgård O; Alm-Kristiansen AH; Ledsaak M; Gabrielsen OS
    Biochem Biophys Res Commun; 2009 Oct; 388(1):150-4. PubMed ID: 19646965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High affinity DNA binding of native full length c-Myb and differential proteolytic sensitivity of its N- and C-terminal domains.
    Krieg J; Oelgeschläger M; Janknecht R; Lüscher B
    Oncogene; 1995 Jun; 10(11):2221-8. PubMed ID: 7784067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra- and intermolecular triplex DNA formation in the murine c-myb proto-oncogene promoter are inhibited by mithramycin.
    Vigneswaran N; Thayaparan J; Knops J; Trent J; Potaman V; Miller DM; Zacharias W
    Biol Chem; 2001 Feb; 382(2):329-42. PubMed ID: 11308031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA polymerase II foci.
    Alm-Kristiansen AH; Saether T; Matre V; Gilfillan S; Dahle O; Gabrielsen OS
    Oncogene; 2008 Aug; 27(34):4644-56. PubMed ID: 18408764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive c-Myb amino-terminal phosphorylation and DNA binding activity uncoupled during entry and passage through the cell cycle.
    Cures A; House C; Kanei-Ishii C; Kemp B; Ramsay RG
    Oncogene; 2001 Mar; 20(14):1784-92. PubMed ID: 11313925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Myb-dependent inositol 1,4,5-trisphosphate receptor type-1 expression in vascular smooth muscle cells.
    Afroze T; Sadi AM; Momen MA; Gu S; Heximer S; Husain M
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1305-11. PubMed ID: 17363689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb.
    Zor T; De Guzman RN; Dyson HJ; Wright PE
    J Mol Biol; 2004 Mar; 337(3):521-34. PubMed ID: 15019774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-myb stimulates cell growth by regulation of insulin-like growth factor (IGF) and IGF-binding protein-3 in K562 leukemia cells.
    Kim MS; Kim SY; Arunachalam S; Hwang PH; Yi HK; Nam SY; Lee DY
    Biochem Biophys Res Commun; 2009 Jul; 385(1):38-43. PubMed ID: 19427836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone H3 tail positioning and acetylation by the c-Myb but not the v-Myb DNA-binding SANT domain.
    Mo X; Kowenz-Leutz E; Laumonnier Y; Xu H; Leutz A
    Genes Dev; 2005 Oct; 19(20):2447-57. PubMed ID: 16195416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumorigenic N-terminal deletions of c-Myb modulate DNA binding, transactivation, and cooperativity with C/EBP.
    Oelgeschläger M; Kowenz-Leutz E; Schreek S; Leutz A; Lüscher B
    Oncogene; 2001 Nov; 20(50):7420-4. PubMed ID: 11704872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.
    Bessa M; Saville MK; Watson RJ
    Oncogene; 2001 Jun; 20(26):3376-86. PubMed ID: 11423988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of c-Myb DNA-binding by RNA polymers.
    Nordgård O; Andersen TØ; Gabrielsen OS
    BMC Biochem; 2004 Nov; 5():15. PubMed ID: 15527501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor.
    Schultz J; Lorenz P; Ibrahim SM; Kundt G; Gross G; Kunz M
    Mol Carcinog; 2009 Jan; 48(1):14-23. PubMed ID: 18459127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.